IL17A and inflammatory bowel disease: One proposed mechanism contributing to IBD pathology lies in the ability of Th17 cells to transition into Th1 cells, rather than in Th17 cells alone [75], potentially explaining why therapy with anti-IL17A monoclonal antibodies was ineffective in CD patients [76].